SCHEMBL2608288

SCHEMBL2608288

C=C(C)C(=O)OCCCCNC(=O)CCC(=O)OC(C)C

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.44
EPHX2 P34913 2/20 0.38
MAPT P10636 1/20 0.36
POLB P06746 1/20 0.36
APEX1 P27695 1/20 0.36
HTT P42858 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
LMNA P02545 2/20 0.36
THRB P10828 1/20 0.36
CASP2 P42575 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
FAAH O00519 1/20 0.33
ALDH1A1 P00352 1/20 0.32
ACHE P22303 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2608291 0.91 TSHR (0.40) TSHREPHX2MAPTHTTLMNA
SCHEMBL12310433 0.86 TSHR (0.49) TSHREPHX2POLBAPEX1HTT
SCHEMBL2608283 0.84 TSHR (0.53) TSHRMAPTPOLBAPEX1HTT
SCHEMBL2608301 0.83 EPHX2 (0.40) TSHREPHX2MAPTPOLBLMNA
SCHEMBL16425943 0.83 THRB (0.45) TSHREPHX2MAPTPOLBAPEX1
SCHEMBL12259950 0.83 TSHR (0.54) TSHREPHX2MAPTPOLBAPEX1
SCHEMBL16309326 0.83 TSHR (0.53) TSHRPOLBAPEX1HTTTDP1
SCHEMBL21115820 0.82 TSHR (0.50) TSHRMAPTPOLBAPEX1HTT
SCHEMBL12259949 0.82 TSHR (0.57) TSHREPHX2MAPTPOLBAPEX1
SCHEMBL2608275 0.82 TSHR (0.46) TSHREPHX2MAPTLMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345180-B2 Display medium for assessment and method for manufacturing same ZEON CORPORATION (JP) 2022-05-31 US disclosed
US-20190184732-A1 DISPLAY MEDIUM FOR ASSESSMENT AND METHOD FOR MANUFACTURING SAME ZEON CORPORATION (JP) 2019-06-20 US disclosed
US-8262932-B2 Polymerizable liquid crystal compound, polymerizable liquid crystal composition, polymer and film FUJIFILM CORPORATION (JP) 2012-09-11 US disclosed
US-8158021-B2 Polymerizable liquid crystal compound, polymerizable liquid crystal composition, liquid crystalline polymer, and optical anisotropic article ZEON CORPORATION (JP) 2012-04-17 US disclosed
US-8158021-B2 Polymerizable liquid crystal compound, polymerizable liquid crystal composition, liquid crystalline polymer, and optical anisotropic article ZEON CORPORATION (JP) 2012-04-17 US disclosed
US-20100258764-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE ZEON CORPORATION (JP) 2010-10-14 US disclosed
US-20100258764-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE ZEON CORPORATION (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100258764-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE LEO1, ZYX, CCNT1 TSHR 4760/4885EPHX2 2270/4885MAPT 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.